pioglitazone + sitagliptin

Pioglitazone + sitagliptin is a fixed-dose combination of two oral antidiabetic agents used in the management of type 2 diabetes mellitus. Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity and increasing glucose uptake in peripheral tissues. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases endogenous incretin levels, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release. The combination provides complementary mechanisms to improve glycemic control, with clinical studies showing greater reductions in hemoglobin A1c compared to monotherapy with either agent[1][2][4][8]. This combination is primarily indicated for adults with type 2 diabetes who require additional glycemic control beyond what can be achieved by monotherapy.

Other names

sitagliptin + pioglitazone